Results of the Treatment and Evaluation of Quality of Life in Patients with High-Grade Cerebral Arteriovenous Malformations after Endovascular Embolization

DOI: https://doi.org/10.30702/ujcvs/23.31(03)/SC034-127133
Keywords: brain malformation, endovascular treatment, intracranial hemorrhage, outcome, modified Rankin Scale, EQ-5D-3L questionnaire

Abstract

Treatment options for cerebral arteriovenous malformations (cAVMs) may include radiosurgery, endovascular embolization, microsurgical removal, or a combination thereof. However, treatment of high-grade (Spetzler–Martin grades IV and V) cAVMs remains extremely challenging when aiming complete occlusion.

The aim. To study the safety of the endovascular embolization in patients with high-grade cAVMs and its impact on the quality of life (QoL).

Materials and methods. Between 2012 and 2022, 174 patients with cAVMs were endovascularly treated at Research and Practical Center for Endovascular Neuroradiology of the National Academy of Medical Sciences of Ukraine with an average follow-up of more than 9 months. Of these patients, 11 (6.3%) and 6 (3.4%) had Spetzler–Martin grade IV and grade V cAVM, respectively. Outcomes after surgical procedures were assessed and QoL was evaluated using standardized EQ-5D-3L questionnaire.

Results. Five (29.4%) patients had intracerebral hemorrhage, 6 (35.3%) had seizures, 5 (29.4%) had other non-hemorrhagic manifestations and 1 (5.9%) patient had a neurological deficit as a result of cerebral steal. In 17 patients, 28 embolization sessions were performed, and in nearly all of them (96%) N-butyl cyanoacrylate was used as the preferred embolic agent. There were no procedural complications. After embolization, three (17.6%) patients had neurologic deterioration (temporary in 2 patients and persistent in 1 patient).

All the patients were alive at the nearest follow-up. After embolization, 2 (11.7%) patients had recurrent hemorrhage, but without additional morbidity. Two of the five patients after cAVM rupture had some degree of disability. With regard to non-hemorrhagic debut, 8 (72%) patients reported symptom reduction. QoL assessment with EQ-5D-3L questionnaire revealed that severe problems were present in 2 (33.3%) of 6 patients after intracerebral hemorrhage and 2 (18.2%) of 11 patients with non-hemorrhagic manifestation. The mean Visual Analogue Scale score for the hemorrhagic group was 76.4 ± 15 points, while the non-hemorrhagic group’s score was 85.2 ± 14 points.

Conclusions. Endovascular embolization, which aims to occlude the bleeding site or improve cerebral steal with a manageable consequence profile, can be used safely in carefully selected patients with high-grade cAVMs. Our experience shows that QoL can be satisfactory in 3/4 of patients after high-grade cAVM embolization, and more data from real-world practice are highly needed to determine the best method and time for improving patient outcomes.

References

  1. Ota T, Komiyama M. Pathogenesis of non-hereditary brain arteriovenous malformation and therapeutic implications. Interv Neuroradiol. 2020;26(3):244-253. https://doi.org/10.1177/1591019920901931
  2. Kim H, Al-Shahi Salman R, McCulloch CE, Stapf C, Young WL; MARS Coinvestigators. Untreated brain arteriovenous malformation: Patient-level meta-analysis of hemorrhage predictors. Neurology. 2014;83(7):590-597. https://doi.org/10.1212/WNL.0000000000000688
  3. Orosz P, Vadász Á, Veres DS, Berentei Z, Gubucz I, Nardai S, et al. Living with a Brain AVM: A Quality of Life Assessment. Acta Neurochir Suppl. 2021;132:71-76. https://doi.org/10.1007/978-3-030-63453-7_10
  4. Shaikh N, Al-Kubaisi A, Mohsin Khan M, Khan A, Mahmood Z, Chanda A, et al. Cerebral Arteriovenous Malformation from Classification to the Management [Internet]. In: Gürer B, Kuru Bektaşoğlu P, editors. Vascular Malformations of the Central Nervous System. IntechOpen; 2020 [cited 2023 Aug 9]. https://doi.org/10.5772/intechopen.86659
  5. Spetzler RF, Martin NA. A proposed grading system for arteriovenous malformations. J Neurosurg. 1986;65(4):476-483. https://doi.org/10.3171/jns.1986.65.4.0476
  6. Winkler EA, Lu A, Morshed RA, Yue JK, Rutledge WC, Burkhardt JK, et al. Bringing high-grade arteriovenous malformations under control: clinical outcomes following multimodality treatment in children. J Neurosurg Pediatr. 2020;26(1):82-91. https://doi.org/10.3171/2020.1.PEDS19487
  7. Kato Y, Dong VH, Chaddad F, Takizawa K, Izumo T, Fukuda H, et al. Expert Consensus on the Management of Brain Arteriovenous Malformations. Asian J Neurosurg. 2019;14(4):1074-1081. https://doi.org/10.4103/ajns.AJNS_234_19
  8. Mohr JP, Parides MK, Stapf C, Moquete E, Moy CS, Overbey JR, et al.; international ARUBA investigators. Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a multicentre, non-blinded, randomised trial. Lancet. 2014;383(9917):614-621. https://doi.org/10.1016/S0140-6736(13)62302-8
  9. Feghali J, Huang J. Updates in arteriovenous malformation management: the post-ARUBA era. Stroke Vasc Neurol. 2019;5(1):34-39. https://doi.org/10.1136/svn-2019-000248
  10. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727-1736. https://doi.org/10.1007/s11136-011-9903-x
  11. Omodaka S, Endo H, Fujimura M, Niizuma K, Sato K, Matsumoto Y, et al. High-grade Cerebral Arteriovenous Malformation Treated with Targeted Embolization of a Ruptured Site: Wall Enhancement of an Intranidal Aneurysm as a Sign of Ruptured Site. Neurol Med Chir (Tokyo). 2015;55(10):813-817. https://doi.org/10.2176/nmc.cr.2015-0052
  12. Krings T, Hans FJ, Geibprasert S, Terbrugge K. Partial “targeted” embolisation of brain arteriovenous malformations. Eur Radiol. 2010;20(11):2723-2731. https://doi.org/10.1007/s00330-010-1834-3
  13. Lv X, Zhang Y, Wang J. Systematic Review of Transcatheter Arterial Embolization of AVM: Indications, Bleeding Complications, Cure Rate, and Long-Term Bleeding Risk. Neurol India. 2020;68(6):1285-1292. https://doi.org/10.4103/0028-3886.304101
  14. Zaki Ghali MG, Kan P, Britz GW. Curative Embolization of Arteriovenous Malformations. World Neurosurg. 2019;129:467-486. https://doi.org/10.1016/j.wneu.2019.01.166
  15. Han PP, Ponce FA, Spetzler RF. Intention-to-treat analysis of Spetzler-Martin grades IV and V arteriovenous malformations: natural history and treatment paradigm. J Neurosurg. 2003;98(1):3-7. https://doi.org/10.3171/jns.2003.98.1.0003
  16. Miyamoto S, Hashimoto N, Nagata I, Nozaki K, Morimoto M, Taki W, et al. Posttreatment Sequelae of Palliatively Treated Cerebral Arteriovenous Malformations. Neurosurgery. 2000;46(3):589-594. discussion 594-595. https://doi.org/10.1097/00006123-200003000-00013
  17. Dicpinigaitis AJ, Ogulnick JV, Mayer SA, Gandhi CD, Al-Mufti F. Increase in Ruptured Cerebral Arteriovenous Malformations and Mortality in the United States: Unintended Consequences of the ARUBA Trial? Stroke Vasc Interv Neurol. 2023;3(1):e000442. https://doi.org/10.1161/SVIN.122.000442
  18. Laakso A, Dashti R, Juvela S, Isarakul P, Niemelä M, Hernesniemi J. Risk of Hemorrhage in Patients With Untreated Spetzler-Martin Grade IV and V Arteriovenous Malformations: A Long-term Follow-up Study in 63 Patients. Neurosurgery. 2011;68(2):372-378. https://doi.org/10.1227/NEU.0b013e3181ffe931
Published
2023-09-28
How to Cite
Shchehlov, D. V., Svyrydiuk, O. Y., Vyval, M. B., Chebanyuk, S. V., Altman, I. V., & Mamonova, M. Y. (2023). Results of the Treatment and Evaluation of Quality of Life in Patients with High-Grade Cerebral Arteriovenous Malformations after Endovascular Embolization. Ukrainian Journal of Cardiovascular Surgery, 31(3), 127-133. https://doi.org/10.30702/ujcvs/23.31(03)/SC034-127133
Issue
Ukrainian Journal of Cardiovascular Surgery Vol 31 No 3 2023
Section
GENERAL ISSUES OF TREATMENT OF PATIENTS WITH CARDIOVASCULAR PATHOLOGY